洛铂与替加氟联合贝伐单抗治疗晚期大肠癌的临床研究.docVIP

洛铂与替加氟联合贝伐单抗治疗晚期大肠癌的临床研究 作者：李保健，吴晓阜，朱瑞霞 【摘要】 目的 探讨洛铂与替加氟注射液(方克)联合贝伐单抗治疗晚期大肠癌的临床疗效及毒副反应。方法 64例晚期大肠癌患者分别接受方案A(32例)、方案B(32例)治疗。方案A组：替加氟800 mg/m2，CIV(24 h)，d1-d5;LV 200 mg/m2，静脉滴注(2 h)，d1～d5;洛铂35 mg/m2，静脉滴注，d1。方案B组：替加氟800 mg/m2，CIV(24 h)d1～d5;LV 200 mg/m2，静脉滴注(2 h)，d1～d5，洛铂35 mg/m2;静脉滴注，d1;贝伐单抗15 mg/kg，静脉滴注，d1。结果 方案A组：CR 3例，PR 7例，有效率31.3%;方案B组：CR 6例，PR 12例，有效率为56.3%，静脉滴注，2组有效率比较，差异有显著性(χ2=4.0635，P=0.044)。2组均未出现明显肝、肾功能及心脏毒性反应。不良反应发生率比较，2组无统计学意义(Pgt;0.05)。结论 洛铂与替加氟联合贝伐单抗是治疗晚期大肠癌安全有效的方案之一，能显著提高晚期患者的有效率，毒副作用可以耐受。 【关键词】 肠肿瘤; 药物疗法; 替加氟; 贝伐单抗; 洛铂; 治疗结果 　　【Abstract】 Objective To explore the lobaplatin and tegafur injection combined with bevacizumab in the treatment of advanced colorectal cancer and its clinical efficacy and toxicity.Methods 64 patients with advanced colorectal cancer were treated with Program A(32 patients)and B(32 patients)in the treatment.Program A: tegafur (Funk)800 mg/m2, CIV(24 h), d1～d5; LV 200 mg/m2, ivgtt(2 h), d1～d5, Luo platinum 35 mg/m2, ivgtt, d1. Program B：tegafur 800 mg/m2, CIV(24 h)d1～d5，LV 200 mg/m2, ivgtt(2 h), d1～d5, Luo platinum 35 mg/m2, ivgtt, d1, bevacizumab15 mg/kg, ivgtt, d1.Results CR in program A: 3 cases, PR: 7 cases, efficiency rate 31.3%; CR in program B: 6 cases, PR: 12 cases, efficiency rate 56.3%; Program B was better than program A.The efficiency of the two groups showed significant difference(X2=4.0635，P=0.044). The two groups showed no apparent liver and kidney function and cardiac toxicity. The incidence of adverse reactions between the two groups was not statistically significant (Pgt;0.05).Conclusion Lobaplatin tegafur combined with bevacizumab is safe and effective in the treatment of advanced colorectal cancer.It can significantly improve the efficiency of the treatment. 　　【Key words】 Intestial neoplasms; Drug therapy; Tegafur; Bevacizumab; Luo platinum; Treatment outcome 　　大肠癌是临床上常见的恶性肿瘤。近年来在我国的发病率呈逐渐上升的趋势。对于晚期、复发转移的大肠癌患者，主要采用全身化疗为主的综合性姑息治疗。我院肿瘤治疗中心对晚期大肠癌患者应用洛铂与替加氟联合贝伐单抗治疗，现